Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182643/?tool=EBI

Similar Items

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin.
Published: (2014-01-01)

Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
by: Adam Obr, et al.
Published: (2014-01-01)

Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia
by: David N. Perdigoto, et al.
Published: (2017-10-01)

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.
by: Clemens Woywod, et al.
Published: (2017-01-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Radhakrishnan Ramchandren, et al.
Published: (2009-05-01)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01)

TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
by: Mateja Grat, et al.
Published: (2004-12-01)

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
by: Camillo Porta, et al.
Published: (2011-12-01)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
by: Omar Prado-Carrillo, et al.
Published: (2022-07-01)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01)

Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
by: Milva Caputo, et al.
Published: (2011-04-01)

Inhibition of LATS kinases reduces tumorigenicity and increases the sensitivity of human chronic myelogenous leukemia cells to imatinib
by: Phatchanat Klaihmon, et al.
Published: (2024-02-01)

Dasatinib-Loaded Erythrocytes Trigger Apoptosis in Untreated Chronic Myelogenous Leukemic Cells: A Cellular Reservoir Participating in Dasatinib Efficiency
by: Kelly Airiau, et al.
Published: (2018-06-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report
by: Scheid Christoph, et al.
Published: (2011-05-01)

Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
by: Monika Conchon, et al.
Published: (2011-01-01)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
by: Rajiv Kumar, et al.

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
by: Jaroslav Jelinek, et al.
Published: (2011-01-01)

A novel case of chronic spontaneous urticaria associated chronic myelogenous leukemia with rapid resolution upon treatment with imatinib
by: Alexis Tracy, MD, et al.
Published: (2022-12-01)

Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
by: Shoumariyeh K, et al.
Published: (2014-09-01)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
by: Fang Cheng, et al.
Published: (2023-04-01)

Correction to: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
by: Zhongzheng Lu, et al.
Published: (2021-12-01)

Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib
by: Naveed Ali, et al.
Published: (2016-03-01)

Apoptosis resistance in chronic myelogenous leukemia
by: Fabíola Attié de Castro, et al.
Published: (2005-09-01)

Bosutinib in the management of chronic myelogenous leukemia
by: Keller-von Amsberg G, et al.
Published: (2013-05-01)

AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects
by: Meher Bolisetti Gayatri, et al.
Published: (2023-10-01)

Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
by: Silvia Catellani, et al.
Published: (2011-04-01)

Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia
by: Pritish K Bhattacharyya
Published: (2013-01-01)

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
by: Shovik Bandyopadhyay, et al.
Published: (2017-01-01)

Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway
by: Xiaobo Zhang, et al.
Published: (2017-08-01)

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl
by: Cao Qi, et al.
Published: (2010-05-01)

Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation
by: E Loveman, et al.
Published: (2012-05-01)

Analysis of telomere length in chronic myelogenous leukemia.
by: Boultwood, J, et al.
Published: (1997)

Analysis or telomere length in chronic myelogenous leukemia
by: Fidler, C, et al.
Published: (1998)